Pfizer Inc.
PFE
NYSE
24.55
USD-0.33(-1.33%)
As of today
Pfizer Inc. stock forum
9 Comments
Ethan Walker@SignalWolf
3 months ago
AstraZeneca and CSPC Pharmaceutical Sign $5.3B AI-Powered Drug Development Deal
AstraZeneca $AZN, the Anglo-Swedish pharmaceutical giant, has announced a new AI-driven research agreement with China’s CSPC Pharmaceutical Group $1093.HK valued at up to $5.3 billion. The deal is des...
Ava Crystal@CrystalViolet
3 months ago
BioNTech Acquires CureVac in $1.25B All-Stock Deal to Expand mRNA Oncology Portfolio
German biotechnology leader BioNTech SE $22UA.F announced on Thursday the acquisition of compatriot and former COVID-19 vaccine rival CureVac N.V. $5CV.DE in an all-stock deal valued at approximately ...
Steven Russell@StockSleuth
4 months ago
Moderna Submits Updated COVID-19 Vaccine to FDA Targeting LP.8.1 Variant Amid U.S. Surge
Moderna, Inc. $MRNA, a leading biotech firm and key player in the mRNA vaccine market, announced on Friday the submission of its updated COVID-19 vaccine candidate to the U.S. Food and Drug Administra...
Emma Collins@WealthInsider
4 months ago
Pfizer Faces Regulatory Roadblock in Prostate Cancer Strategy
Pfizer Inc. $PFE recently encountered a significant hurdle in its oncology ambitions. The company aimed to broaden the label for Talzenna, a medication currently available for prostate cancer patients...
Ethan Brooks@InvestPro
4 months ago
Pfizer’s Record-Breaking Licensing Move Signals Growing Appetite for Chinese Biotech Innovation
Pfizer Inc. $PFE has solidified its commitment to global oncology leadership by paying a landmark upfront fee of USD 1.25 billion for the license to manufacture an experimental cancer therapy develope...
GoldRiders@GoldRiders
4 months ago
Pfizer to Invest Up to $6 Billion in China’s 3SBio for Cancer Drug License
U.S. pharmaceutical giant Pfizer Inc. $PFE has announced a major licensing and investment agreement with China-based 3SBio Inc. $1530.HK to accelerate the development of a promising cancer therapy. Th...